Orexo publishes bond prospectus and applies for listing of its bond loan on NASDAQ OMX Stockholm

Orexo publishes bond prospectus and applies for listing of its bond loan on
NASDAQ OMX Stockholm

Uppsala, Sweden – June 9, 2014 – On 30 April 2014, Orexo AB (publ) announced
that the company had decided to issue a SEK 500 million bond loan within a total
framework amount of SEK 1,000 million on the Swedish bond market. The tenure of
the bond is 4 years and it has an annual coupon of STIBOR (3 month) + 4.00
percent.

The company has applied for listing of the bonds on NASDAQ OMX Stockholm. The
application has been approved by NASDAQ OMX Stockholm and the first day of
trading will be 10 June 2014. In relation to the listing, the company has
prepared a prospectus which has been approved by the Swedish Financial
Supervisory Authority. The prospectus is available on the company’s website
www.orexo.com, and on the website of the Swedish Financial Supervisory Authority
www.fi.se.

For further information, please contact:
Henrik Juuel, EVP and CFO Tel: +46 (0)722-20 94 77, E-mail: ir@orexo.com

About Orexo AB
Orexo AB is a specialty pharma company with commercial operations in the United
States and R&D in Sweden developing improved treatments using proprietary drug
delivery technology. The company is commercializing its proprietary product,
Zubsolv® (buprenorphine and naloxone), in the United States for maintenance
treatment of opioid dependence. Zubsolv is a novel sublingual formulation of
buprenorphine and naloxone using Orexo’s extensive knowledge in sublingual
technologies. Orexo has a portfolio of two approved and revenue generating
products currently marketed under license in the EU, US and Japan. Orexo’s
development expertise is within the area of reformulation technologies, and
especially sublingual formulations. Orexo AB, with its headquarters in Sweden,
is listed on NASDAQ-OMX. The largest shareholders are Novo A/S and HealthCap.

For information about Orexo, please visit www.orexo.com

Orexo AB (publ) discloses the information provided herein pursuant to the
Financial Instruments Trading Act and/or the Securities Markets Act. The
information was submitted for publication at 5:30 pm CET on June 9, 2014.